The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains

T cell malignancies are a group of hematologic cancers with high recurrence and mortality rates. CD5 is highly expressed in ~85% of T cell malignancies, although normal expression of CD5 is restricted to thymocytes, T cells, and B1 cells. However, CD5 expression on chimeric antigen receptor (CAR)-T cells leads to CAR-T cell fratricide. Once this limitation is overcome, CD5-targeting CAR-T therapy could be an attractive strategy to treat T cell malignancies. Here, we report the selection of novel CD5-targeting fully human heavy-chain variable (FHV) domains for the development of a biepitopic CAR, termed FHVH\textsubscript{3}/V\textsubscript{H1}, containing FHVH\textsubscript{1} and FHVH\textsubscript{3}, which were validated to bind different epitopes of the CD5 antigen. To prevent fratricide in CD5 CAR-T cells, we optimized the manufacturing procedures of a CRISPR-Cas9-based CD5 knockout (CD5KO) and lentiviral transduction of anti-CD5 CAR. In vitro and in vivo functional comparisons demonstrated that biepitopic CD5KO FHVH\textsubscript{3}/V\textsubscript{H1} CAR-T cells exhibited enhanced and longer lasting efficacy; produced moderate levels of cytokine secretion; showed similar specificity profiles as either FHVH\textsubscript{1}, FHVH\textsubscript{3}, or the clinically tested H65; and is therefore suitable for further development.

INTRODUCTION

In recent years, advances have been made in chimeric antigen receptor T cell (CAR-T) therapy to target B cell malignancies, induce remission, and improve long-term relapse-free survival in patients with B cell leukemia and lymphoma.\textsuperscript{1,2,3} However, the overall prognosis of refractory or relapse (r/r) T cell malignancies is much poorer compared to B cell malignancies, and salvage chemotherapy regimens remain the best treatment for patients with r/r T cell leukemia or lymphoma.\textsuperscript{4,5,6} Therefore, it is imperative to develop effective CAR-T cell therapies to fight T cell malignancies.

CD5 is constitutively expressed on normal T cells and present in ~85% of T cell malignancies.\textsuperscript{7} It contains three scavenger receptor cysteine-rich (SRCR) domains,\textsuperscript{8,9,10,11} which act as inhibitory regulators of both T cell receptor (TCR) and B cell receptor (BCR) signaling and serve as a target for evolutionary immunotherapeutic strategies against T cell malignancies.\textsuperscript{12,13} In addition, CD5 is also frequently expressed in some B cell malignancies, with expression in normal tissues restricted to thymocytes, T cells, and a small subpopulation of B cells (B1 cells).\textsuperscript{14,15} The data from a phase I clinical trial (Clinical-Trials.gov: NCT03081910) conducted by Baylor College of Medicine demonstrated that CAR-T cells incorporated a murine-derived single-chain variable fragment (scFv) H65 targeting CD5 were safe and had anti-tumor activity in patients with r/r T cell malignancies.\textsuperscript{9} However, the patients who obtained an objective response post-infusion without receiving planned hematopoietic stem cell transplantation relapsed with their latent CD5\textsuperscript{+} malignancy after a few weeks.\textsuperscript{9} Clearly, improvements in the efficacy and persistence of CD5-targeting CAR-T cell therapies for T cell malignancies are urgently needed. The limited lifespan of CAR-T cells in patients may be related to the fratricide of anti-CD5 CAR-T cells and human anti-mouse antibody responses, whereas the application of CD5 knockout (CD5KO) fully human (FH) antibody-derived CAR-T cells may extend the survival and optimal function of CAR-T cells.\textsuperscript{2,22,25}

Herein, we report the selection of novel FH heavy-chain variable (V\textsubscript{H}) domains and the rational development of a fratricide-resistant, CD5-targeting biepitopic CAR-T therapy. Initially, using a high-quality FH phage display library developed in house containing $8.32 \times 10^{18}$ V\textsubscript{H} domains, through panning, primary screening, and identification, we obtained some V\textsubscript{H}8 that specifically bind to recombinant CD5 protein and cell surface CD5. We hypothesized that the tandem use of V\textsubscript{H} domains targeting different epitopes could potentially enhance the function of CAR-T cells and minimize the risk of tumor escape due to antigen mutation. Therefore, through competitive binding fluorescence-activated cell sorting (FACS) analysis, FHVH\textsubscript{1} and FHVH\textsubscript{3}, two V\textsubscript{H} domains that bind to different epitopes of CD5, were identified.
Next, to prolong CAR-T cell persistence, we applied a 4-1BB co-stimulatory domain in the design of the CAR construct that has been reported to possess the capacity to promote CAR-T cell survival and subsequently optimized the CD5 knockout and lentiviral transduction steps to successfully generate anti-CD5 CAR-T cells that resist fratricide. Furthermore, the functions of degranulation, cytotoxicity, cytokine release, expansion, and persistence of H65, FHVH1, FHVH3, and biepitopic FHVH3/VH1 CAR-T cells were confirmed in vitro and in vivo. FHVH3/VH1 CAR-T cells exhibited potent and longer lasting efficacy and specificity profiles similar to those of clinically used H65. This biepitopic CAR is currently being prepared for further evaluation and development.

RESULTS

Screening and selection of FH CD5-specific VH domains
A diagram of the screening and selection procedure is shown in Figure 1A. The VH domains were screened from a phage display library comprising both naive and synthetic VH domains by three rounds of protein panning after enrichment (Table S1). A total of 92 monoclonal antibodies were selected for enzyme-linked immunosorbent assay (ELISA) and validated using CD5+ Jurkat and CD5−/C0 Raji cells for FACS screening, of which 38 clones specifically bound to CD5 protein, without binding to other control proteins, and the representative clones are shown in Figure 1B. After sequencing, 29 unique clones were identified. The binding specificity of these 29 clones with additional CD5− cell lines was further characterized by FACS analysis. Of these, four clones (FHVH1–4) were confirmed to bind to another human-derived CD5+ cell line (CCRF-CEM; Figure 1C). To further measure their binding affinities to the CD5 antigen, these VH clones, along with H65, were expressed in VH/scFv-human immunoglobulin Fc fragment (hFc) or VH/scFv-rabbit immunoglobulin Fc fragment (rFc) format and purified. Binding affinity was determined using the Octet96e system. FHVH1 (KD = 1.63 × 10⁻² M), FHVH2 (KD = 8.32 × 10⁻² M), and FHVH3 (KD = 1.39 × 10⁻² M) showed slightly lower but comparable binding affinity to CD5 protein compared with H65 (KD = 6.53 × 10⁻¹ M), although FHVH4 (KD = 2.47 × 10⁻² M) exhibited substantially lower affinity than the above clones (Figure S1).

Identification of VH domains against different epitopes of CD5 and specificity validation of anti-CD5 biepitopic antibodies
A diagram of the anti-CD5 VH domains competitive binding assay is shown (Figure 2A). H65, FHVH1, and FHVH3 CAR-T cells all bind to CD5 antigen, and interestingly, H65-hFc and FHVH3-hFc antibodies...
did not affect the binding of FHVH3 CAR-T cells to CD5 antigen, suggesting that FHVH1 binds different CD5 antigen epitopes with H65 and FHVH3, although FHVH3 recognizes the overlapping epitope of CD5 as H65 (Figure 2B). Having demonstrated that FHVH1 and FHVH3 bind different CD5 antigenic epitopes, we hypothesized that the use of FHVH1 and FHVH3 antibodies in tandem may both enhance the efficacy and reduce the risk of tumor escape caused by antigenic mutations. Before functional validation, we validated the binding specificity of anti-CD5 antibodies to determine whether the tandem use of FHVH1 and FHVH3 alters their specificity. The results suggested that FHVH1, FHVH3, and FHVH3/VH1 antibodies specifically bind CD5+ cells (Jurkat and CCRF-CEM), but not CD5− cells, from different tissue sources (Figures 2C and S2). FHVH3/VH1 antibody was also verified with membrane proteome array (MPA) specificity validation to test for reactivity against approximately 5,900 different membrane protein clones representing more than 90% of the human membrane proteome, with no significant non-specific binding detected (Figure 2D). In addition, the binding affinity of FHVH3/VH1-hFc (K_D = 7.01 × 10⁻¹⁰ M) was barely changed compared to that of either FHVH1-hFc (K_D = 1.63 × 10⁻⁹ M) or FHVH3-hFc (K_D = 1.39 × 10⁻⁹ M; Figure S1). However, the FHVH1/VH3-hFc antibody showed non-specific binding to CD5− cells (CCRF-CD5KO and Raji) and was excluded from further functional comparisons. Size-exclusion, high-performance liquid chromatography (SEC-HPLC) results suggested that the FHVH3/VH1-hFc antibody migrated as the major peak (>93%) with a retention time of 11.457 min, although the FHVH1/VH3-hFc antibody showed four peaks, with the main peak occupying 45.51% of the total peak area with a retention time of 11.948 min (Figure S3), indicating instability of the FHVH1/VH3-hFc antibody.

Process optimization of CD5KO and lentiviral transduction eliminate fratricide of anti-CD5 CAR-T cells

FHVH1, FHVH3, FHVH3/VH1, and H65 were incorporated into a second-generation CAR consisting of CD5 antigen recognition domains, a CD8α hinge/transmembrane region, 4-1BB co-stimulatory domain,
and intracellular CD3γ coupled in frame with a truncated epidermal growth factor receptor (EGFRt) through a T2A sequence (Figure 3A). In preliminary studies, we found that the expression of CAR molecules on CD5+ CAR-T cells decreased gradually, although the expression of CD5 increased, and apoptotic T cells accounted for the majority of CAR+ T cells (CD5+ H65 CAR-T cells 53.6% ± 11.1%; n = 3; Figure S4). To address the potential fratricide issue of CAR-T cells, we optimized the procedures of T cell CD5KO and lentiviral transduction of anti-CD5 CAR. Schematic diagrams of 3 different strategies to generate CD5KO anti-CD5 CAR-T cells are shown in Figure S4A. We found that T cells transduced with anti-CD5 CAR lentivirus 24 h after CD5KO showed stable expression of CAR molecules on the cell surface, without CD5 recurrence; expressed relatively low levels of apoptosis (CD5KO/CD5LV H65 CAR-T cells 23.8% ± 7.0%; CD5KO/2hLV H65 CAR-T cells 10.3% ± 1.4%; n = 3; Figures S4B–S4D); and improved CD5+ tumor cell cytolytic capacity (Figure S4E). After electroporation with Cas9 protein and CD5-specific guide RNA (gRNA-7), loss of surface CD5 expression was detected 3 days after electroporation (generally >80%; Figure 3B). Generation of CAR-T cells deficient in CD5 expression was performed as shown in Figure 3C. CD5KO and expression of anti-CD5 CAR did not affect the CD4/CD8 ratio of primary T cells (Figure 3D). Furthermore, apoptosis was not significantly enhanced in any of the CD5KO anti-CD5 CAR-T cells containing 4-1BB co-stimulatory domain compared to either the CD5KO-T cells or mock T cells and also not among the CAR+ T cells in either of the four CAR-T cell groups (p > 0.05; n = 3; Figure 3E). This indicates that the loss of CD5 overcomes the unintended fratricide and dysfunction of CAR-T cells. The transduction efficiency of CD5 CARs detected with EGFRt antibody was consistent with the CD5 antigen binding rate, and the CD5 antigen binding/EGFRt median fluorescence intensity (MFI) ratio of FHvH3/VH1 CAR was also not significantly different from that of either the H65, FHvH1, or FHvH3 CARs (p > 0.05; n = 3; Figures 3F and 3G). FHvH1 CAR had a lower CD5 antigen binding/EGFRt MFI ratio than that of the H65 CAR, indicating that the expression degree of FHvH1 CAR on the surface of T cells was lower than that of H65 CAR (p < 0.05; n = 3; Figure 3G). The expression of CD5 CARs was easily detected through the expression of EGFRt in primary T cells, and the transduction of activated CD5KO-T cells with lentiviral vectors resulted in efficient CAR expression (Figure 3H). Moreover, CAR expression on CD5KO-T cells remained stable during in vitro culture (Figure 3I). The CD5 antigen expression on the surface of anti-CD5 CAR-T cells was analyzed on days 5–7 and 12–15, and, with the exception of FHvH1 CAR-T cells, CD5 expression on the surface of H65, FHvH3, and FHvH3/VH1 CAR-T cells was less than 1% on days 12–15 (Figure 3J), in accordance with the requirements for CAR-T cell product manufacturing. The majority of CD5KO anti-CD5 CAR-T cells displayed a naive-like surface phenotype that might have an enhanced capacity for expansion, differentiation, and self-renewal upon antigen stimulation (Figures 3K and 3L).28

CD5KO anti-CD5 biepitopic CAR-T cells exhibited enhanced degradation and cytotoxicity against malignant T cell lines in vitro

CD5 is widely expressed in T cell malignancies. We found that CCRF-CEM and Jurkat cell lines were highly CD5 expressing, MOLT-4 and SUP-T1 were moderately CD5 expressing, and CCRF-CD5KO, K562, and Raji were CD5− (Figure 4A). CD5KO anti-CD5 CAR-T cells expressed significantly higher levels of the T cell activation markers CD69 and CD25 after co-culture with CCRF-CEM, but not after co-culture with CCRF-CD5KO (p < 0.0001; Figures 4B and 4C). FHvH1 CAR-T cells stimulated by CD5+ target cells CCRF-CEM showed a slightly higher median fluorescence intensity of Fas ligand (FasL) than either FHvH3/VH1, FHvH3, or H65 (p < 0.05; Figure 4D), although T cells showed both enhanced killing activity against tumor cells and an increased risk of activation-induced cell death (AICD) as a result of augmented FasL expression.29,30

Degranulation was a prerequisite for CAR-T cell perforin-granzyme-mediated killing. CD5KO anti-CD5 CAR-T cells upregulated CD107a (a surrogate marker for degranulation) expression in a CD5-specific manner, and FHvH3/VH1 CAR-T cells exhibited significantly higher degranulation compared to either FHvH1, FHvH3, or H65 after CD5 antigen stimulation (p < 0.0001; Figure 4E). Next, the cytotoxicity of CD5KO anti-CD5 CAR-T cells was assessed using a luciferase-based assay. CD5KO anti-CD5 CAR-T cells selectively killed tumor cells expressing different CD5 antigen densities in a dose-dependent manner. CD5KO anti-CD5 CAR-T cells showed robust cytotoxicity against CD5+ tumor cell lines at the indicated effector to
Figure 4. CD5KO anti-CD5 CAR-T cells were compared functionally
(A) Surface expression of CD5 (red solid histograms) in T-ALL and T-lymphoma cell lines in comparison with isotype control (dotted line gray histograms) measured using flow cytometry. (B) Expression of the early T cell activation marker CD69 on anti-CD5 CAR-T cells following a 24-h co-incubation with CCRF-CEM or CCRF-CD5KO (gated on CD8+ EGFR+ cells) is shown. The data represent mean ± SD (n = 3). ****p < 0.0001 (two-way ANOVA). (C) Expression of the T cell activation marker CD25 on anti-CD5 CAR-T cells following co-incubation as described in (B) is shown (gated on CD8+ EGFR+ cells). The data represent mean ± SD (n = 3). ****p < 0.0001 (two-way ANOVA). (D) Median (legend continued on next page)
target ratios, whereas they were not cytotoxic against the CD5− cell lines CCRF-CD5KO, K562, and Raji (Figure 4F), demonstrating that the cytolyis was CD5 specific. In particular, CDSKO anti-CD5 biepito
car-T cells exhibited greater cytotoxicity in vitro than either FHV13/VH1, FHV13, or H65, especially when co-incubated with malignant T cell lines with moderate expression of CD5 antigen at relatively low effector to target (E:T) ratios (Figure 4F). Similarly, compared to either FHV13, FHV13, or H65 CAR-T cells, biepito
car-T cells exhibited higher levels of degranulation and greater cytotoxicity after in vitro co-incubation with K562-CD5 L1–3 stable cell lines with relatively low levels of CD5 antigen expression (Figure S5).

Moreover, all four types of CAR-T cells produced the pro-inflamma
tory cytokines tumor necrosis factor alpha (TNF-α) and interferon (IFN)-γ in response to CD5+ CCRF-CEM cells (Figure 5A). Except for H65, respectively FHV13, FHV13, and FHV13/VH11 CAR-T cells showed elevated levels of interleukin-2 (IL-2) release when co-incubated with CCRF-CEM cells. Notably, FHV13/VH11 CAR-T cells secreted lower levels of CD5 antigen-specific TNF-α and IL-2 than both FHV13 and FHV13 CAR-T cells. Therefore, cytoytic degranu
dation between CAR-T cells and target cells is assumed to be one of the main mechanisms leading to better anti-tumor activity of biepito
car FHV13/VH11 CAR-T cells. It also suggested that the tandem CAR construct of FHV13 and FHV13 may not exacerbate the risk of cyto
drome (CRS) although possessing enhanced tumor-killing capacity. Collectively, FHV13/VH11 CAR-T cells demonstrated potent and specific tumor-killing activity against CD5+ cells.

CDSKO anti-CD5 biepito
car-T cells exhibited an excellent expansion after repeated antigen stimulation in vitro

The expansion capacity of CAR-T cells in an environment of contin
cious exposure to target antigen is critical for eradicating the large tumor burden and maintaining sustained remission. To this end, we sought to assess the expansion potential, expression of exhaustion markers, and apoptosis levels of CAR-T cells in vitro over multiple cycles of antigen stimulation. FHV13/VH11 CAR-T cells exhibited significantly higher proliferation than FHV11 (p < 0.05) and slightly higher proliferation than FHV13 and H65 (no significant difference; p > 0.05) after five rounds of mitomycin-C-treated CCRF-CEM cell stimulation (Figure 5B). The apoptosis levels of anti-CD5 CAR-T cells were not significantly different in both CD4+ and CD8+ subsets before and after stimulation with mitomycin-C-treated CCRF-CEM cells (Figure 5C). Furthermore, FHV13/VH11 CAR-T cells expressed lower levels of LAG-3 and TIM-3 after the 7th stimulation in CCRF-CEM cells than H65 CAR-T cells, and T cell immunoreceptor with Ig and ITIM do
mains (TIGIT) expression levels of FHV11 CAR-T cells were higher than those of H65 CAR-T cells (p < 0.001; Figure 5D).

CDSKO anti-CD5 biepito
car-T cells demonstrated superior antitumor activity in vivo

After completing the functional validation of CD5 CAR-T cells in vitro, we established a mouse tumor model of T cell acute lymphoblastic leu
kemia (T-ALL) by tail intravenous injection of CCRF-CEM-FLIuc cells to verify the in vivo efficacy of CD5 CAR-T cells. We tested the ability of CD5 CAR-T cells administered on days 4 and 7 post-engraftment to suppress leukemia progression. The results showed that FHV13/VH11 CAR-T cells cleared T-ALL cells earlier than FHV11 and FHV13 CAR-T cells and maintained a longer remission than FHV11 and FHV13 CAR-T cells, whereas the same dose of H65 CAR-T cells only had a weak antitumor effect (Figure 6A). The relative percentage of CD45+ EGFR+ T cells in the peripheral blood on days 10 and 17 was detected using flow cytometry. The frequency of FHV13/VH11 CAR-T cells was significantly higher than that of FHV11 CAR-T cells on day 17 (p < 0.01), although there was no significant difference in the frequency of either H65 or FHV13 CAR-T cells (p > 0.05; Figure 6B). The relative percentages of H65, FHV13, and FHV13/VH11 CAR-T cells was significantly higher on day 17 than on day 10 (p < 0.01), whereas FHV11 CAR-T cells did not show significant expansion (p > 0.05; Figure 6B). All CARs were effective in prolonging the survival of tumor-bearing mice (Figure 6C). Importantly, in contrast to the mice receiving either H65 CAR-T or CDSKO-T cells, which showed massive leukemic burden by bioluminescence imaging (BLI), the mice treated with FHV13/VH11 CAR-T cells were practically leukemia free by day 21, whereas the mice administered FHV11 and FHV13 CAR-T cells appeared to have tumor recurrence (Figure 6D). There was no significant difference in body weight of these mice among six groups (Figure 6E).

Subsequently, we performed the quantitative determination of Th1/
Th2 cytokines in the serum of PBS- or CAR-T/T-treated mice on day 17 after CCRF-CEM cell infusion. We detected high levels of IFN-γ and IL-10 in the serum of mice in the H65 CAR-T cell treat
ment group collected on day 17 (Figure 6F). TNF-α, IL-2, IL-4, and IL-6 were barely detectable in the serum of all groups of mice collected on day 17, and TNF-α, IFN-γ, IL-2, IL-4, IL-6, and IL-10 were under
dectable in the serum of all groups of mice collected on day 10 (data not shown). In addition, the results of flow cytometry analysis showed that FHV13/VH11 CAR-T cells in the peripheral blood of tumor
bearing mice collected on day 24 exhibited lower levels of LAG-3 and TIM-3 than H65 CAR-T cells (Figures 6G and 6H).

In the xenograft mouse model established by SUP-T1 cells with mod
erate CD5 expression, after infusion of 2 × 10^6 CAR+ T cells per mouse, H65 and FHV13 CAR-T cells temporarily inhibited and controlled cancer progression but failed to eradicate neoplastic cells.

fluorescent intensity of FasL on anti-CD5 CAR-T cells following co-incubation as described in (B) is shown (gated on CD8+ EGFR+ cells). The data represent mean ± SD for three donors. ****p < 0.0001 (two-way ANOVA).

(E) The degranulation assay of four CARs is shown. CAR-T cells were stimulated with target cells expressing different CD5 antigen densities. The CD5 antigen-specific increase in CD107a was assessed as a measure of degranulation. The data represent mean ± SD for three donors. ***p < 0.001 (two-way ANOVA). (F) Anti-CD5 CAR-T cells selectively kill CD5+ tumor cells. All CARs lyse CD5+ target cells in a close-dependent manner. The killing ability of CAR-T/T cells for CD5+ cell lines was determined by luciferase-based cytotoxicity assay after 24 h incubated with target cells at different E:T ratios. The data indicate mean ± SD from three co-cultures. *p < 0.05, **p < 0.01, and ***p < 0.0001 (two-way ANOVA).
In contrast, FHVH3/VH1 and FHVH1 CAR-T cells eliminated neoplastic cells in mice at an early stage, and FHVH3/VH1 CAR-T cells significantly prolonged the suppression of leukemia compared with FHVH1 CAR-T cells (p < 0.0001; Figures 7A and 7B). To evaluate the expansion and persistence of CAR+ T cells, the percentage of CD45+ EGFR+ cells in the peripheral blood of mice was determined using flow cytometry on days 13, 20, and 26. The results demonstrated that FHVH3/VH1 CAR-T cells on day 26 showed significant expansion compared to day 13 and day 20 (p < 0.05), although the frequency changes of CAR-T cells in other groups were not significantly different (p > 0.05; Figure 7C). Moreover, the survival time of the tumor-bearing mice in either the FHVH3/VH1 or FHVH1 CAR-T-cell-treated groups was significantly longer than that in either the H65 or FHVH3 CAR-T-cell-treated groups (Figure 7D).

**DISCUSSION**

As shown in a recent clinical trial, CAR-T therapy targeting CD5 is an attractive strategy in patients with r/r CD5+ T cell malignancies without resulting in a life-threatening immunodeficiency. However, preliminary data from the clinical trial using murine-derived H65 CAR-T therapy indicated a good safety profile but modest...
Figure 6. The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by CCRF-CEM

(A) Average radiance quantification of each treatment group measured at the indicated time points. The results are displayed as mean ± SEM (n = 5). *p < 0.05 and ****p < 0.0001 (two-way ANOVA). (B) Relative frequency of CD5KO anti-CD5 CAR-T cells (CD45+ EGFR+) in peripheral blood of mice on days 10 and 17 is shown, respectively (n = 3). **p < 0.01 (two-way ANOVA). (C) Overall Kaplan-Meier survival curve is shown. Survival curves were compared using the log rank test. Mice treated with CAR-T cells showed significantly increased survival (**p < 0.001) compared with those of CD5KO-T and PBS-treated groups. (D) Growth and staging of the tumor monitored by bioluminescence imaging are shown. (E) Body weight curve is shown. The results are displayed as mean ± SEM (n = 5). (F) Concentration of IFN-γ and IL-10 in the serum of indicated groups collected on day 17 is shown. The results are displayed as mean ± SD (n = 5). *p < 0.05 and ****p < 0.0001 (one-way ANOVA). (G) Representative flow cytometry analysis shows the proportion of LAG-3+ and TIM-3+ cells in CAR-T cells in the peripheral blood of NCG mice collected on day 24. (H) Quantification and statistical analysis of the results in (G) are shown. The results are displayed as mean ± SD (n = 3). *p < 0.05 and **p < 0.01 (two-way ANOVA).
non-persistent efficacy (44% of patients obtained an objective response). Self-activation and fratricide caused by expression of CD5 antigen on the anti-CD5 CAR-T cells may contribute to poor persistence, which in turn leads to CD5 tumor recurrence. Therefore, to fully utilize the potential of anti-CD5 CAR-T cell therapy and address the concerns of human anti-mouse immune responses, we developed a fratricide-resistant biepitopic CAR-T therapy derived from original FH CD5 VH5. Recently, several preclinical studies of FH single-domain, antibody-derived CAR-T cell therapies have demonstrated in vitro and in vivo functions similar to those of murine scFv-derived benchmarks, such as CD33-targeting VH (CAR33VH) and B cell maturation antigen (BCMA)-targeting VH (FHVH33).31,32 CARs derived from FH heavy-chain-only binding domains have significant advantages over scFv-binding domains. Heavy-chain-only binding domains simplify the structural design of CARs, and the smaller size of VH domains has potential steric advantages over the larger scFv domains in accessing cryptic antigenic epitopes.33,34 Through three rounds of CD5 antigen panning, we successfully enriched and obtained phage VH clones that were validated by FACS and ELISA to bind specifically to the CD5 antigen. Using a competitive FACS assay and specificity validation assay, we obtained two FH VH domains (FHVH1 and FHVH3) that specifically bind to different epitopes of CD5. Biepitopic FHVH3/VH1 antibody was verified with MPA specificity validation and binding test to cell lines of different tissue origins to further ensure specificity and safety. Notably, we found that the structural arrangement of VH domains is one of the factors affecting the stability of biepitopic antibodies.

Subsequently, to further compare the function of candidate CAR molecules and to eliminate the adverse effects of fratricide on CAR-T cells, we performed optimization of CD5 knockout and lentiviral transduction of primary T cells. After optimization, the CRISPR-Cas9-based CD5 knockout efficiency of T cells was above 80% and CAR expression rates of fratricide-resistant CD5 CAR-T cells remained stable. As a negaive regulator of antigen-receptor-mediated signaling in thymocytes and T cells, CD5 knockout in mice did not induce changes in populations of T and B lymphocytes compared to control mice.12,35,36 Recently, Alotaibi et al.37 reported that functionally blocking CD5 signaling resulted in enhanced antitumor immunity and elevated T cell activation. Chun et al.38 demonstrated that CD5 knockout enhances the anti-tumor activity of CAR-T cells by enhancement of CAR-mediated activation and proliferation. In our study, CD5 knockout did not alter the CD4/CD8 ratio and phenotype of T cells and was able to prevent activation-induced cell death and dysfunction of CAR-T cells due to autoantigen stimulation.

By applying the optimized procedures, we performed a functional comparison of tandem VH CARs using either linkers of different sizes, flexibilities, and amino acid compositions or VH domains connected in different orders (i.e., VH1-VH3 or VH3-VH1). These tandem CAR constructs are shown in Figure S6A. All tandem CARs could be successfully expressed on the surface of T cells; however, FHVH1 (EAAAK) × 1 VH3 CAR-T cells were shown to have poorer ability to eliminate CD5+ T cells than other tandem CARs (p < 0.01; Figures S6B and S6C). The functional comparison revealed that the tandem VH CAR construct with a long flexible (G4S)3-linker, with lower levels of CD107a background, had relatively robust degranulation and cytokotoxicity against high or moderate CD5-expressing target cells, higher levels of TNF-α release, and comparable IFN-γ release, compared to other constructs (Figures S6D–S6F). This indicates the importance of linker selection and connected order of tandem VH domains for the structural stability and functional performance of CARs.

Afterward, we compared the in vitro and in vivo functions of biepitopic FHVH3/VH1 CAR-T cells with H65, FHVH1, and FHVH3 CAR-T cells targeting a single epitope. As expected, FHVH3/VH1 CAR-T cells exhibited stronger CD5 antigen-specific degranulation and killing ability than either H65, FHVH1, or FHVH3 CAR-T cells, especially for tumor cells with moderate expression of CD5 antigen. Remarkably, FHVH3/VH1 CAR-T cells showed excellent expansion and persistence and did not express higher levels of exhaustion markers and activation-induced cell death than the other groups of CAR-T cells in both in vivo and in vitro target antigen stimulation assays. In addition, despite the significant functional enhancement, FHVH3/VH1 CAR-T cells maintained relatively modest cytokine secretion, which might not exacerbate CRS and neurotoxicity in patients after infusion.

To further strengthen our hypothesis that tandem VH domains targeting different epitopes could potentially enhance the function of CAR-T cells, wild-type CD5-expressing and mutated CD5-expressing K562 cell lines were generated and utilized for the localization of functional epitopes recognized by anti-CD5 CAR-T cells (Figures S7A–S7C). FHVH3/VH1 and FHVH1 CAR-T cells showed increased degranulation after stimulation by K562-CD5-DX23 but neither H65 nor FHVH3 CAR-T cells (Figure S7D), indicating that H65 and FHVH3 CAR-T cells could only bind the membrane-distal region (epitope near D1), whereas FHVH3/VH1 and FHVH1 CAR-T cells could recognize the membrane-proximal region (epitope near D2). Chimeric TCRβ CTL targeting membrane-proximal CD22 epitope was reported to show potent degranulation and cytotoxicity compared to those binding to membrane-distal epitope.39 In our study, FHVH1 CAR, targeting membrane-proximal epitope, exhibited stronger cytotoxicity and cytokine release compared to the membrane-distal epitope targeting CAR (H65 and FHVH1). In addition, ...
potentially lower immunogenicity, the FHVH3/VH1 CAR may also
future clinical studies. Moreover, due to its superior ef
mined by
varying degrees of expression of human CD5 molecules, as deter-
CEM by CRISPR-Cas9. K562-CD5 L1
Fisher Scienti
(pancreatic epithelioid carcinoma) were cultured in DMEM (Corn-
adenocarcinoma), NCI-H460 (large cell lung cancer), 293CT/293T
HCT-116 (colorectal carcinoma), HEPG2 (hepatocellular carci-
rpmi-1640 medium containing 10% fetal bovine serum (FBS)
DXX3.
DXX3.
FHVH3/VH1 CAR-T cell degranulation compared to stimulation
with K562-CD5-DX23 (p < 0.0001; Figure S7D), reflecting a signifi-
cant synergistic effect. Xu et al. previously reported the development
of a biepitopic llamas-derived BCMA-targeting CAR-T therapy and
applied this system to achieve a better objective response rate, com-
plete remission rate, and lower relapse rate than monovalent
BCMA CAR-T therapy in clinical trials. With a similar conceptual
basis and excellent preclinical results, we speculate that FHVH3/VH1
CAR-T cells could also demonstrate favorable efficacy and safety in
future clinical studies. Moreover, due to its superior efficacy and
potentially lower immunogenicity, the FHVH3/VH1 CAR may also
be of interest when used for “off-the-shelf” universal anti-CD5
CAR-T/CAR-NK therapy.

CAR-T therapy targeting CD5 has good clinical application prospects
beyond just in the treatment of T cell malignancies; with high expres-
sion on a subset of B cell malignancies, it can also be used to treat B cell
malignancies, such as mantle cell lymphoma, diffuse large B cell
lymphoma, and chronic lymphocytic leukemia or small-cell lymphocytic
lymphoma. Furthermore, application of CAR-T therapy to target
multiple antigens simultaneously is an attractive strategy for treatment
and prevention of antigen-loss relapses, and V\textsubscript{H} binding domains
furthermore ease the design of multispecific CARs. The use of two
V\textsubscript{H} domains can simplify the design of bispecific CAR constructs
capable of recognizing different antigens compared to the design utilizing
two scFv domains. Therefore, FHVH1 and FHVH3 are suitable for
further use in the design of bispecific or even multispecific CAR struc-
tures to solve critical problems in current cancer drug development,
such as clonal heterogeneity and antigen escape.

MATERIALS AND METHODS

Cell lines
CD5⁺ cell lines, Jurkat (acute T cell leukemia), CCRF-CEM (acute T
lymphoblastic leukemia), MOLT-4 (acute T lymphoblastic leukemia),
SUP-T1 (T cell lymphoblastic lymphoma), and the CD5⁺ cell lines,
K562 (chronic myelogenous leukemia), Raji (Burkitt’s lymphoma),
and NALM-6 (acute B-lymphocytic leukemia), were cultured in
RPMI-1640 medium containing 10% fetal bovine serum (FBS)
(Thermo Fisher Scientific, Waltham, MA, USA), QT6 (fibrosarcoma),
HCT-116 (colorectal carcinoma), HEPG2 (hepatocellular carci-
noma), MDA-MB-468 (breast adenocarcinoma), OVCAR3 (ovarian
adenocarcinoma), NCI-H600 (large cell lung cancer), 293CT/293T
(embryonic kidney), KATO III (gastric carcinoma), and PANC-1
(pancreatic epithelioid carcinoma) were cultured in IMDM (Corns-
ing, Corning, NY, USA) medium containing 10% FBS (Thermo
Fisher Scientific). All cell lines were verified before use. CCRF-
CD5KO is a human CD5 knockout cell line generated from CCRF-
CEM by CRISPR-Cas9. K562-CD5 L1-5 are stable cell lines with
varying degrees of expression of human CD5 molecules, as deter-
mined by flow cytometry sorting. K562-CD5-D123 expresses all three
CD5 SRCR domains, named D1, D2, and D3. K562-CD5-DX23 dele-
tion mutant lacks D1, and D1 and D2 were removed from K562-CD5-
DXX3.

Screening for FH anti-CD5 V\textsubscript{H} domains
A FH heavy-chain-only phage display antibody library (IMARS;
Nanjing IASO Biotherapeutics, Nanjing, China) was used to generate
anti-CD5 V\textsubscript{H} domains by optimal protein panning. In brief, three
rounds of bead panning were performed using CD5-hFc-Bio as the
target antigen and CD19-hFc-Bio as the counterpart. After three
rounds of panning, the CD5-specific phages were enriched. The
phage clones were first tested for their ability to bind to recombinant
CD5 via ELISAs using plates coated with CD5-hFc-Bio (Kactus Bio-
systems, Shanghai, China)/CD5-His (ACRO Biosystems, Newark,
DE, USA) and streptavidin or control antigen CD19-hFc-Bio (ACRO
Biosystems)/BAFFR-His-Bio (Kactus Biosystems) and
streptavidin (Pierce, Rockford, IL, USA). KO7 (M13KO7 helper
phage; Invitrogen, Waltham, MA, USA) served as a negative control.
The specificity of these clones to Jurkat/Raji was evaluated by flow cy-
tometry. After sequencing, to validate the binding specificity of
unique clones, their binding affinities to multiple CD5⁺ (Jurkat and
CCRFCEM) and CD5⁺ (Raji and K562) cell lines were further
confirmed using flow cytometry. Clones with good specificity to
both recombinant CD5 protein and cell lines were constructed using
CARs and immunoglobulin G (IgG) proteins for further analysis. The
anti-CD5 biepitopic CAR and IgG protein vector constructs
involved FHVH1 and FHVH3. In the IgG protein vector constructs, the
two clones were linked by a flexible (G4S)-linker with either the V\textsubscript{H}1
at the N terminus (V\textsubscript{H}1-V\textsubscript{H}3) or the V\textsubscript{H}3 at the N terminus (V\textsubscript{H}3-
V\textsubscript{H}1). Tandem V\textsubscript{H}1 CARs used either linkers of different sizes, flexibil-
ities, and amino acid compositions or V\textsubscript{H}1 domains connected in
different orders (i.e., V\textsubscript{H}1-V\textsubscript{H}3 or V\textsubscript{H}3-V\textsubscript{H}1).

Generation of CD5KO anti-CD5 CAR-T cells
FH anti-CD5 V\textsubscript{H} domains and the control H65 scFv were graft
ed into a second-generation CAR with a CD8z hinge/transmembrane region,
4-1BB co-stimulatory domain, and intracellular CD3ζ, with the CD5
CAR gene linked to a EGFRt by a T2A sequence for further transla-
tional and clinical research.

Lentivirus was generated using Lipofectamine3000 (Invitrogen) by transient
transduction of Lenti-X293T cells with pspAX2 and pMD2.G pack-
aging plasmids. The viral supernatants were collected at either 48 h
or 72 h after transduction of Lenti-X293T cells with psPAX2 and pMD2.G pack-
aging plasmids. The viral supernatants were collected at either 48 h
or 72 h after transduction, filtered, concentrated, aliquoted, and
stored at −80°C.

Human donor peripheral blood leukocytes from healthy donors were
used for in vitro and in vivo CAR-T/T functional validation. The pro-
tocol was approved by the Institutional Review Board of Tongji Hos-
pital, Tongji Medical College, Huazhong University of Science and
Technology. Appropriate informed consent was obtained from all do-
ners before specimen collection, following the Declaration of Helsinki.
Peripheral blood mononuclear cells (PBMCs) were isolated from
the collected blood leukocytes via density gradient centrifugation using Fi-
coll-Paque Plus (GE Healthcare, Boston, MA, USA). CD3⁺ T cells from
PBMCs were purified with CD3 microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions.
Then, T cells were cultured in X-VIVO 15 medium (Lonza, Basel,
Switzerland) supplemented with 10% FBS (Thermo Fisher Scientific), 100 U/mL IL-2 (Sigma-Aldrich, St. Louis, MO, USA), and activated with Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific). After 1 day of activation, the CD5 gene was genomically disrupted in primary human T cells using a Cellectrix electroporation system (Cellectrix, Manassas, VA, USA) following the manufacturer’s instructions.48 Then, CD5KO-T cells were transduced with lentivirus at a multiplicity of infection of 2–5 1 day later. Following electroporation, T cells were incubated in X-VIVO 15 medium supplemented with 10% FBS in the presence of IL-7 (40 ng/mL; Novoprotein Scientific, Summit, NJ, USA) and IL-15 (50 ng/mL; Novoprotein Scientific).

**CD5 antigen binding assay and competitive binding FACS analysis of VH domains**

For the antigen binding detection, CD5KO CAR-T and mock T cells (1 x 10⁶) were harvested and incubated for 1 h at 4°C with CD5-hFc-Bio (0.4 μg/mL; Kactus Biosystems), washed twice, and then incubated with allophycocyanin (APC)-conjugated streptavidin (BioLegend, San Diego, CA, USA) before subjected to flow cytometry analysis.

For the competitive binding assay, CD5KO CAR-T and mock T cells (1 x 10⁶) were co-cultured with a pre-mixed solution of FHVs/hFc (10 μg/mL) or H65-hFc (10 μg/mL) and CD5-His (0.4 μg/mL; ACROBiosystems) for 1 h at 4°C, respectively. After washing twice, the cells were incubated with APC-conjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), and the cells were analyzed using flow cytometry.

**Specificity validation of anti-CD5 biepitopic antibodies**

For specificity analysis of biepitopic antibodies, FHVs/hFc and FHVs/Vh1 were engineered into full-length antibody formats with human or rabbit IgG1 Fc regions. CD5⁺ cell lines (1 x 10⁶) and CD5⁻ cell lines (1 x 10⁶) were harvested and incubated for 1 h at 4°C with either isotype control, FHVs/hFc, FHVs/Vh1, FHVs/Vh1/Vh3, or FHVs3/Vh1 antibody (10 μg/mL); washed twice; incubated with either APC-conjugated anti-human IgG antibody (polyclonal; Jackson ImmunoResearch Laboratories) or phycoerythrin (PE)-conjugated anti-rabbit IgG antibody (clone: Poly4064; BioLegend); and then analyzed using flow cytometry.

**MPA specificity validation**

Specificity testing of FHVs/Vh1 using MPA was accomplished by Integral Molecular (Philadelphia, PA, USA). The MPA comprises approximately 5,900 different membrane protein clones, representing more than 90% of the human membrane proteome. The binding activity across the protein library was measured on an Intellicyt iQue (Essen BioScience, Ann Arbor, MI, USA), whereas each target identified with MPA screening was reaffirmed in a second flow cytometry experiment after continuous dilutions of FHVs/Vh1 antibody, as previously described.49

**Flow cytometry-based assays**

The cell lines were stained with APC-conjugated mouse anti-human CD5 antibody (clone: UCHT2; BD PharMingen, San Diego, CA, USA) and isotype antibody (clone: MOPC-21; BioLegend) to determine the CD5 antigen expression level.

PE or APC-conjugated EGFR antibody (clone: A13), fluorescein isothiocyanate (FITC)-conjugated CD8 (clone: SK1), PE/cyanine7-conjugated CD4 (clone: A161A1), BV421-conjugated FasL (clone: NOK-1), BV421-conjugated CCR7 (clone: G043H7), APC-conjugated CD45RA (clone: HI100), FITC-conjugated CD8 (clone: SK1), BV421-conjugated TIM-3 (clone: F38-2E2), APC-conjugated LAG-3 (clone: 7H2C65), PE/cyanine7-conjugated TIGIT (clone: A15153G), and FITC-conjugated CD45 (clone: H130) antibodies were all purchased from BioLegend. CAR-T cells (4 x 10⁵ CAR⁻) were co-incubated with equal tumor cells for 24 h and then the activation markers CD69 and CD25 were detected with BV421-conjugated CD69 antibody (clone: FN50; BioLegend) and FITC-conjugated CD25 antibody (clone: BC96; BioLegend) and the activation-induced surface expression of FasL was also detected. For T cell exhaustion detection, CAR-T cells (1 x 10⁵ CAR⁻) were co-incubated with equal CCRF-CEM cells for 48 h and then equal amounts of CCRF-CEM cells were added again and incubated for another 48 h and repeated seven times in total. After that, the exhaustion markers TIM-3, LAG-3, and TIGIT were detected with BV421-conjugated TIM-3, APC-conjugated LAG-3, and PE/cyanine7-conjugated TIGIT antibodies. The data were acquired with MACS Quant Analyzer 10 (Miltenyi Biotec) and analyzed with FlowJo software version 10 (Tree Star, Ashland, OR, USA).

**Apoptosis assays**

Apoptotic cell death was analyzed by annexin V/phosphatidylinositol (PI) staining, and CD5KO CAR-T/T cells (5 x 10⁵) were harvested and stained with FITC Annexin V Apoptosis Detection Kit with PI (BioLegend) following the manufacturer’s instructions and then subjected to flow cytometry analysis to detect apoptosis.

**Degranulation**

For the degranulation assay, CD5KO CAR-T cells were co-incubated with different target cells for 4 h in the presence of 1:50 PE/cyanine7-conjugated CD107α antibody (clone: H4A3; BioLegend) and 1:500 monensin (BioLegend), and CD107α was detected using flow cytometry.

**Cytolysis assays**

To determine the cytotoxicity of CD5KO anti-CD5 CAR-T cells against CD5⁺ cell lines, Jurkat, CCRF-CEM, MOLT-4, SUP-T1, CCRF-CD5KO, K562, and Raji cell lines were stably transduced with firefly luciferase via lentivirus, and the monoclonal stably fLuc-expressing cell lines were generated by limiting dilution. For CAR-T cell killing assays, target cells (2 x 10⁶) were plated in U-bottom 96-well plates in triplicate with CD5KO anti-CD5 CAR⁺ T/T cells at specified E:T ratios and incubated for 24 h. Luciferase assay was performed using the Steady-Glo Luciferase assay system (Promega, Madison, WI, USA) according to the manufacturer’s instructions.
CBA-based, cytokine-releasing assays
Cytokine-releasing assays were performed by co-incubating $2 \times 10^5$ CAR+ T/T cells with $4 \times 10^5$ target cells at a 1:2 ratio. After further culture for 24 h, the supernatants were collected for cytokine level measurement using a Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit II (BD Biosciences) according to the manufacturer’s instructions. The quantitative determination of cytokines in the serum of PBS- or CAR-T/T-treated mice was also performed using CBA.

Repeat antigen stimulation expansion
For the repeat antigen stimulation expansion assay, on day 0, CCRF-CEM cells were plated in 6-well plates treated with mitomycin C at a final concentration of 1 $\mu$g/mL. On day 1, mitomycin-C-treated CCRF-CEM cells ($3 \times 10^5$) were washed six times with PBS and then mixed with $3 \times 10^5$ viable CAR-T cells in 24-well plates with X-VIVO 15 medium supplemented with IL-2. On day 4, new CCRF-CEM cells were treated as on day 0, viable CAR-T cells were counted, and $3 \times 10^5$ CAR-T cells from the 24-well plates that expanded were re-mixed with $1 \times 10^5$ mitomycin-C-treated CCRF-CEM cells as on day 1. This process was repeated five times. Fold expansion after each stimulation was calculated as (viable CAR-T cells on day 1) / (viable CAR-T cells on day 0), whereas the cumulative expansion was calculated by the following equation: expansion fold(s) = (fold expansion$_{day 4}$) / (fold expansion$_{day 1}$).

Mouse xenograft models
Animal experiments were accomplished by GemPharmatech (Nanjing, China). The protocol and procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of GemPharmatech before the experiments began. The animals were handled in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 6-week-old female NOD-Prkdc[emo26G452Il2rgm26G427/N] (NOD-Prkdc[emo26G452Il2rgm26G427/N] mice were engrafted with $1 \times 10^6$ CCRF-CEM-firefly luciferase cells via tail injection on day 0. Then, the mice were treated by infusion with $2 \times 10^6$ and $1 \times 10^6$ CAR+ T cells via tail injection on days 4 and 7 ($n = 5$ for each group). In the cancer model established by SUP-T1, 6-week-old female NCG mice were engrafted with $1 \times 10^6$ SUP-T1-firefly luciferase cells via tail injection on day 0. Then, the mice were treated by infusion with $2 \times 10^6$ CAR+ T cells via tail injection on day 5 ($n = 6$ for each group). The leukemic burden was evaluated using bioluminescence imaging, and body mass and survival were monitored.

Antibody affinity measurement
The binding affinity of FHV271, FHV103, FHV103/VH11, and H65 antibodies to CD5 was measured using the Octet96e system (Fortebio, Menlo Park, CA, USA). In brief, anti-CD5 antibodies were diluted to 20 $\mu$g/mL with loading buffer and loaded at ~0.8 nM onto the biosensors. After a 60-s equilibration phase, the binding kinetics of the CD5 antigen were monitored at multiple antigen concentrations (12.5–400 nM). Each concentration was tested for 160 s of association and 300 s of disassociation. The binding kinetics were analyzed using a 1:1 binding site model (Biacore X100 version 2.0; Cytiva, Marlborough, MA, USA).

SEC-HPLC assays
The SEC-HPLC analysis was performed using an Alliance HPLC Waters 2695 Separation Module attached to a Waters UV detector (Milford, MA, USA). Samples were analyzed with a TSK 3000SWxl column (5 $\mu$m; 300 x 7.5 x 300 mm). Each sample (30 $\mu$L) was injected, and separation was performed at a flow rate of 0.8 mL/min. The mobile phase consisted of 300 mM NaCl and 50 mM sodium phosphate at pH 6.8. The total run time was 20 min, and UV detection was performed at 280 nm. Empower 3 software (Waters) was used for the data evaluation.

Intracellular cytokine staining assays
Intracellular cytokine staining assays were performed by co-incubating $1 \times 10^6$ CDSKO CAR+ T/T cells with $5 \times 10^5$ indicated target cells at a 1:1 ratio; brefeldin A (BioLegend) and monensin (BioLegend) were added 1 h after plating according to the manufacturer’s instructions. After further culture for 4 h, cells were incubated with antibodies for surface markers and permeabilized for 20 min using BD FACS Permeabilizing Solution 2, followed by staining with PE-conjugated TNF-α (clone: MAb11; BioLegend) and PE/cyanine7-conjugated IFN-γ (clone: 4S.B3; BioLegend) antibodies.

Graphs and statistical analysis
Graphs and data analyses were performed using GraphPad Prism Software version 8.3.0. Some of these graphs were obtained and modified from Servier Medical Art. Unless otherwise stated, all data are representative of at least three independent experiments. All data are presented as mean ± SD except for mouse tumor radiance quantification and body weight data shown as mean ± SEM. Significant differences were analyzed by one-way analysis of variance, two-way analysis of variance, or log rank test. p values are represented as either not significant (ns), *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.

Data availability statement
The data that support the findings of this study are available from the corresponding authors upon reasonable request.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.ymthe.2021.07.001.

ACKNOWLEDGMENTS
The study was sponsored by Nanjing IASO Biotherapeutics. The authors thank Guangrong Meng, Wei Cheng, and Xuefeng Wu for providing CAR constructs and Guang Hu for excellent technical assistance.

AUTHOR CONTRIBUTIONS
J.Z., T.T., and Z.D. designed this study. Z.D., W.M., Y.Z., X.J., J.L., and Q.W. performed the experiments and collected and analyzed the data.
Z.D. wrote the manuscript. J.Z., T.T., Z.D., and W.M. reviewed and revised this manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
T.T., Y.Z., X.J., J.L., and Q.W. are employees of Nanjing IASO Biotherapeutics and held interests in the company. J.Z., T.T., Z.D., Y.Z., X.J., J.L., and Q.W. are among inventors of patent applications related to the fully human heavy-chain-only CD5 antibodies and CARs. J.Z. is a nonpaid member of Scientific and Medical Advisory Board of Nanjing IASO Biotherapeutics.

REFERENCES
1. Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, I.J., Miklos, D.B., Jacobson, C.A., Braunschweig, J., Oluolwe, O.O., Siddiqui, T., Lin, Y., et al. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544.
2. Jacobson, C.A. (2019). CD19 chimeric antigen receptor therapy for refractory aggressive B-cell lymphoma. J. Clin. Oncol. 37, 328–335.
3. Hirayama, A.V., Gauthier, J., Hay, K.A., Voutsinas, J.M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B.S., et al. (2019). The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR T cells. Blood 133, 1876–1887.
4. Davila, M.L., Riviere, I., Wang, X., Barrido, P., Curran, K., Chung, S.S., Wu, Q., Wu, D., Chen, W., Ying, T., Zhu, Z., Liao, X., et al. (2019). 284 cytokulatory domain enhancing cytotoxic activity of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49.
5. Gill, S., Frey, N.V., Hexer, E.O., Lacey, S.F., Melenhorst, J.J., Byrd, J.C., Metzger, S., Jacobson, C.A. (2019). CD19 chimeric antigen receptor therapy for refractory aggres-
6. Jain, N., Lamb, A.V., Olofsson, B., Arger, D., Gurney, J., Triche, T., Stiff, P., et al. (2013). Impact of CD5 on the T cell receptor and CD8 T cell responses to CD5 CAR T cells in patients with advanced hematologic malignancies. Blood 122, 2239–2242.
7. Winter, S.S., Dunsmore, K.P., Devidas, M., Wood, B.L., Easwalr, N., Chen, Z., Eisenberg, N., Broege, N., Hayashi, R.J., Gastier-Foster, J.M., et al. (2018). Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J. Clin. Oncol. 36, 2926–2934.
8. Jain, N., Lamb, A.V., O’Brien, S., Ravandi, F., Konopleva, M., Jabbour, E., Zuo, Z., Jorgensen, J., Lin, P., Pierce, S., et al. (2016). Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127, 1863–1869.
9. Hill, L.C., Rouse, R.H., Smith, T.S., Yang, L., Srinivasan, M., Zhang, H., Perconti, S., Mehta, B., Dakhova, O., et al. (2019). Safety and anti-tumor activity of CD5 CAR T cells in patients with relapsed/refractory T-cell malignancies. Blood 134, 199.
10. Tabebkh, M., Mokrani-Hammani, M., Bismuth, G., and Mami-Chouaib, F. (2013). T-cell modulatory properties of CD5 and its role in antitumor immune responses. Oncoimmunology 2, e228411.
11. Huang, H.I., Jones, N.H., Strominger, J.L., and Herzenberg, L.A. (1987). Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1(T1)(CD5). Proc. Natl. Acad. Sci. USA 84, 204–208.
12. Perez-Villar, J.J., Whitney, G.S., Bowen, M.A., Hewgill, D.H., Aruffo, A.A., and Kanner, S.B. (1999). CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase (SHP-1). Mol. Cell. Biol. 19, 2903–2912.
13. Leonard, J.E., Johnson, D.E., Shwaller, D.L., and Dillman, R.O. (1988). Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model. Cancer Res. 48, 4862–4867.
14. LeMaistre, C.F., Rosen, S., Frankel, A., Kornfeld, S., Saria, E., Meneghetti, C., Drajesk, J., Fulthow, D., Scannap, P., and Byers, V. (1991). Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78, 1173–1182.
15. Mamikonin, M., Rouse, R.H., Tashiro, H., and Brenner, M.K. (2015). A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983–992.
16. Mamikonin, M., Mukherjee, M., Srinivasan, M., Sharma, S., Gomes-Silva, D., Mo, F., Kencurete, G., Orange, I.S., and Brenner, M.K. (2018). Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol. Res. 6, 47–58.
17. Xu, Y., Liu, Q., Zhong, M., Wang, Z., Chen, Z., Zhang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2019). 284 cytokulatory domain enhancing cytotoxic activity of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49.
18. Brossard, C., Semichon, M., Trautmann, A., and Bismuth, G. (2003). CD5 inhibits Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Cancer Res. 63, 1869–1873.
19. Sullivan, G.C., Collins, J.K., and Shanahan, F. (1996). The Fas coun-
20. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. (2016). CD19 CAR T-cell therapy for the selective treatment of T-cell malignancies. Cancer Immunol. Res. 4, 126.
21. Raiker, S.S., Fleischer, L.C., Moot, R., Fedanov, A., Paik, N.Y., Knight, K.A., Doering, C.B., and Spencer, H.T. (2017). Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. OncoImmunology 7, e407898.
22. Lamers, C.H.I., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., and Gratama, J.W. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72–82.
23. Chun, I., Kim, K.H., Chiang, Y.-H., Xie, W., Lee, Y.G.P., Pajarillo, R., Rotolo, A., Shestova, O., Huang, J., Abdel-Mohsen, M., et al. (2020). CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells. Blood 136, 51–52.
24. Philipson, B.I., O’Connor, R.S., May, M.J., June, C.H., Albelda, S.M., and Milone, M.C. (2020). 4–1BB costimulation promotes CAR T-cell survival through noncanonical NF-κB signaling. Sci. Signal. 13, eaay8248.
25. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwar, V.R., et al. (2015). 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590.
26. Cieri, N., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bergoni, C., Peccatori, J., Ciceri, F., et al. (2013). IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–584.
27. Philipson, B.I., Alonzo, M.B., O’Connor, R.S., May, M.J., June, C.H., Albelda, S.M., and Milone, M.C. (2020). 4–1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci. Signal. 13, eaay8248.
32. Lam, N., Trinkel, N.D., Buelow, B., Patterson, G.H., Ojha, N., and Kochenderfer, J.N. (2020). Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat. Commun. 11, 283.
33. Holliger, P., and Hudson, P.J. (2005). Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126–1136.
34. Kumar, M., Keller, B., Makalou, N., and Sutton, R.E. (2001). Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 12, 1893–1905.
35. Azzam, H.S., Grinberg, A., Lui, K., Shen, H., Shores, E.W., and Love, P.E. (1998). CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J. Exp. Med. 188, 2301–2311.
36. Tarakhovsky, A., Müller, W., and Rajewsky, K. (1994). Lymphocyte populations and immune responses in CD5-deficient mice. Eur. J. Immunol. 24, 1678–1684.
37. James, S.E., Greenberg, P.D., Jensen, M.C., Lin, Y., Wang, J., Till, B.G., Raubitschek, A.A., Forman, S.J., and Press, O.W. (2008). Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180, 7028–7038.
38. Xu, J., Chen, L.-J., Yang, S.-S., Sun, Y., Wu, W., Liu, Y.-F., Xu, J., Zhuang, Y., Zhang, W., Weng, X.Q., et al. (2019). Exploratory trial of a biepitopic CAR T cell targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc. Natl. Acad. Sci. USA 116, 9543–9551.
39. Fan, X., Zhuang, Q., Wang, P., Wang, L., Yang, L., Hao, J., Zhao, D., and He, X. (2020). Human CAR-T cells targeting B-cell maturation antigen with dual epitope specificity. Immunology 161, 121–131.
40. Miyazaki, K., Yamaguchi, M., Suzuki, R., Kobayashi, Y., Maeshima, A.M., Nitsu, N., Ennishi, D., Tamaru, J.I., Ishizawa, K., Kashimura, M., et al. (2011). CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann. Oncol. 22, 1601–1607.
41. Zhao, P., Li, L., Zhou, S., Qiu, L., Qian, Z., Liu, X., Meng, B., and Zhang, H. (2019). CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol. Oncol. 37, 360–367.
42. Wang, H.-Y., and Zu, Y. (2017). Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry. Arch. Pathol. Lab. Med. 141, 1236–1246.
43. De Munter, S., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Weening, K., Kerre, T., Abken, H., and Vandekerckhove, B. (2018). Nanobody based dual specific CARs. Int. J. Mol. Sci. 19, 403.
44. Gundry, M.C., Brunetti, L., Lin, A., Mayle, A.E., Kitano, A., Wagner, D., Hsu, J.I., Hoegenauer, K.A., Rooney, C.M., Goodell, M.A., and Nakada, D. (2016). Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep. 17, 1453–1461.
45. Dai, Z., Hu, X., Jia, X., Liu, J., Yang, Y., Niu, P., Hu, G., Tan, T., and Zhou, J. (2021). Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. J. Cell. Physiol. 236, 5832–5847.